Quick Ratios
Quarterly Results
Profit & Loss
Balance Sheet
Cash Flow
Ratios
Mkt Cap
Market Capitalization
₹7Cr
Floriculture/Tissue Culture
Rev Gr TTM
Revenue Growth TTM
-16.95%
Peer Comparison
Compare up to 10 companies side by side across valuation, profitability, and growth.

GVBL
VS
| Quarter | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|
|
Growth YoY Revenue Growth YoY% | | -94.2 | 250.0 | -94.0 | -100.0 | 166.7 | 200.0 | 450.0 | | -43.8 | -57.1 | -77.3 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating Profit Operating ProfitCr |
| 93.0 | 50.0 | 42.9 | 50.0 | | 81.3 | 71.4 | 68.2 | 0.0 | 22.2 | 0.0 | 20.0 |
Other Income Other IncomeCr | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Interest Expense Interest ExpenseCr | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Depreciation DepreciationCr | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|
Growth YoY PAT Growth YoY% | 553.3 | -93.5 | -66.7 | 102.3 | -104.1 | 333.3 | 650.0 | 700.0 | -100.0 | -84.6 | -100.0 | -93.8 |
| 98.0 | 50.0 | 28.6 | 50.0 | | 81.3 | 71.4 | 72.7 | -30.8 | 22.2 | 0.0 | 20.0 |
| 3.1 | 0.1 | 0.1 | 0.1 | -0.1 | 0.4 | 0.5 | 0.5 | -0.3 | 0.1 | 0.0 | 0.0 |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|
|
| -65.2 | 259.0 | 304.8 | 34.7 | 65.7 | -14.1 | -75.4 | -66.1 | 3,758.2 | -93.9 | 411.3 | -41.9 |
| 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 2 | 0 | 0 | 0 |
Operating Profit Operating ProfitCr |
| -248.6 | -421.6 | -23.4 | 16.9 | 42.0 | 65.0 | -66.3 | -535.5 | 32.3 | 8.9 | 52.1 | 6.1 |
Other Income Other IncomeCr | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
Interest Expense Interest ExpenseCr | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Depreciation DepreciationCr | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | -1 | 0 | 1 | 0 | 0 | 0 |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
|
| -318.5 | -3,871.6 | 79.5 | 149.7 | 582.0 | 23.0 | -295.5 | 98.3 | 7,040.5 | -97.7 | 2,245.5 | -114.0 |
| -27.8 | -307.1 | -15.5 | 5.7 | 23.6 | 33.8 | -268.7 | -13.2 | 23.8 | 9.2 | 42.2 | -10.2 |
| 0.0 | -1.1 | -0.2 | 0.1 | 0.8 | 0.9 | -1.8 | 0.0 | 2.1 | 0.1 | 1.2 | -0.1 |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|
Equity Capital Equity CapitalCr | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| 2 | 2 | 1 | 1 | 2 | 2 | 1 | 0 | 0 | 0 | 1 | 1 |
Current Liabilities Current LiabilitiesCr | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 0 |
Non Current Liabilities Non Current LiabilitiesCr | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 1 | 0 | 0 | 0 | 0 |
Total Liabilities Total LiabilitiesCr |
Current Assets Current AssetsCr | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 3 | 3 | 3 | 3 |
Non Current Assets Non Current AssetsCr | 6 | 6 | 6 | 7 | 7 | 8 | 7 | 3 | 2 | 1 | 2 | 2 |
Total Assets Total AssetsCr |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Operating Cash Flow Operating Cash FlowCr | 0 | -1 | 0 | 1 | -1 | 0 | 1 | -2 | -1 | 0 | 0 |
Investing Cash Flow Investing Cash FlowCr | -1 | 1 | 0 | -1 | 0 | 0 | -2 | 4 | 2 | 0 | 0 |
Financing Cash Flow Financing Cash FlowCr | 0 | 0 | 0 | 0 | 1 | 0 | 0 | -2 | -1 | 0 | 0 |
|
Free Cash Flow Free Cash FlowCr | 0 | -1 | 0 | 0 | -1 | 0 | 0 | 3 | 1 | 0 | 0 |
| -1,088.7 | 205.3 | -508.2 | 2,561.3 | -446.1 | 152.9 | -265.6 | 22,799.3 | -120.1 | -132.2 | 7.5 |
CFO To EBITDA CFO To EBITDA% | -121.6 | 149.5 | -337.7 | 868.5 | -250.7 | 79.5 | -1,075.4 | 563.6 | -88.6 | -136.2 | 6.1 |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Valuation Ratios Valuation Ratios |
Market Cap Market CapitalizationCr | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11 | 18 |
Price To Earnings Price To Earnings | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 694.2 | 50.1 |
Price To Sales Price To Sales | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 62.4 | 21.3 |
Price To Book Price To Book | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 3.0 | 4.6 |
| -7.7 | -1.6 | -6.8 | 7.3 | 3.4 | 2.6 | -11.1 | 0.0 | -0.1 | 718.7 | 40.6 |
Profitability Ratios Profitability Ratios |
| 83.2 | 33.1 | 77.9 | 92.4 | 95.2 | 108.0 | 60.8 | 97.3 | 41.8 | 100.0 | 76.1 |
| -248.6 | -421.6 | -23.4 | 16.9 | 42.0 | 65.0 | -66.3 | -535.5 | 32.3 | 8.9 | 52.1 |
| -27.8 | -307.1 | -15.5 | 5.7 | 23.6 | 33.8 | -268.7 | -13.2 | 23.8 | 9.2 | 42.2 |
| -0.2 | -6.5 | -1.3 | 1.1 | 3.8 | 5.9 | -5.4 | 1.4 | 18.4 | 0.4 | 11.3 |
| -0.2 | -7.3 | -1.5 | 0.8 | 4.9 | 5.7 | -12.5 | -0.3 | 18.4 | 0.4 | 9.1 |
| -0.1 | -5.5 | -1.1 | 0.5 | 3.2 | 3.6 | -7.3 | -0.3 | 14.7 | 0.3 | 8.2 |
Operational Ratios Operational Ratios |
Solvency Ratios Solvency Ratios |
Liquidity Ratios Liquidity Ratios |
### **Overview**
Genomic Valley Biotech Ltd. (GVBL) is a diversified biotechnology company integrating **genomics, artificial intelligence (AI), and advanced agricultural technologies** to drive innovation across **healthcare, agriculture, and industrial biotechnology**. Headquartered in India, GVBL operates at the intersection of science, technology, and sustainability, offering B2B research services and B2C personalized solutions in genomics and high-tech farming.
---
### **Core Business Segments**
#### **1. Genomic Healthcare & Molecular Diagnostics**
GVBL leverages **Next-Generation Sequencing (NGS)** and **AI-driven bioinformatics** to provide precision medicine and early disease detection, with a strong focus on oncology.
- **Advanced Genomic Testing Services (as of Dec 2024):**
- Whole Genome Sequencing
- Exome Sequencing
- Targeted Sequencing Panels
- Gut Microbiome Analysis
- Genetic Risk Screening for cancer, diabetes, cardiovascular diseases, and hereditary disorders
- **Oncology Focus:**
- AI-powered cancer diagnostics and personalized treatment plans based on genetic profiling
- Discovery of novel biomarkers and therapeutic targets using NGS and machine learning
- Development of **radiogenomics** platforms combining imaging and genomic data for improved cancer diagnosis and therapy personalization
- **Genetic Counseling & Preventive Care:**
- Offers genetic counseling to help patients interpret results and make informed healthcare decisions
- Supports preventive healthcare through early identification of genetic predispositions
- **Strategic Collaborations:**
- Partnership with **Artemis Hospital, Gurgaon**, for access to state-of-the-art NGS wet-lab facilities
- Plans to build an **in-house wet-lab** for NGS and Molecular Genetics to scale operations and reduce turnaround time
- **R&D Strategy:**
- Focus on translational research in **human genomics and oncology**
- Integration of **AI/ML** to accelerate genomic data analysis and improve diagnostic accuracy
- Extramural research collaborations with academic and industry partners to advance genomic medicine
---
#### **2. Research Process Outsourcing (RPO) & Biotech Innovation**
GVBL serves as a global partner for genomic research, offering end-to-end RPO services.
- **RPO Services:**
- Advanced genomic data analysis using dedicated bioinformatics teams and proprietary software tools
- Support for global researchers in NGS-based studies and AI-integrated diagnostics
- **Future Vision:**
- Position GVBL as a **global hub for biotech innovation**, integrating **genomics, AI, and IT**
- Expand RPO offerings to support pharmaceutical clients in **targeted drug development and gene therapy**
- Pioneer scalable **biomanufacturing processes** for biologics and regenerative medicines
---
#### **3. Agri-Tech & Sustainable Farming Solutions**
GVBL is a leader in **modern, sustainable agriculture**, combining agri-technology with entrepreneurship to empower farmers and meet market demand.
- **High-Tech Cultivation Technologies:**
- **Environment-controlled polyhouses** for year-round cultivation
- **Nutrient Film Technique (NFT)** for leafy greens and herbs
- **Deep Flow Technique (DFT)** for tomatoes, cucumbers, and larger crops
- **Plant Tissue Culture Laboratory** for high-yield, disease-free planting material
- **Innovative Pest Management:**
- Collaboration with an Israeli partner to introduce a **spray-free, lure-based pest control system** targeting female oriental fruit flies using Gravity-Controlled Fluid Release (GCFR)
- Eliminates chemical spraying, promoting organic and eco-friendly farming
- **Drone & Precision Agriculture:**
- Active implementation of **drone technology** from Israel for field mapping, crop monitoring, and precision spraying
- Use of **IoT, GPS, and satellite imagery** for data-driven farm management and input optimization
- **Farmers Producer Company (FPC):**
- Established in 2020–2023, aggregating **~300 small farmers** into a corporate platform
- Ensures **minimum profit guarantees** for farmers and shared business returns
- Produces high-value fruits, vegetables, and medicinal plants (e.g., Aloe vera)
- **Agri Consultancy & Services:**
- Offers **tailored agri-farming advisory** to farmers and High-Net-Worth Individuals (HNIs)
- Provides **turnkey cultivation projects**, including land prep, polyhouse setup, crop selection, and buy-back assurance
- Operates **Khad Beej Bhandar** – a high-tech agri-input shop
---
#### **4. Integrated Farm-to-Consumer Ecosystem**
GVBL has built a vertically integrated agricultural value chain from farm to consumer.
- **Farm 2 Doorstep (farm2doorstep.com):**
- Direct-to-consumer online platform delivering fresh, chemical-free produce to households in the **National Capital Region (NCR)**
- Eliminates middlemen, reduces costs, and ensures superior quality
- Supported by in-house packaging and logistics
- **Supply Chain Strategy:**
- Focus on **five pillars**: product quality, customer service, cost efficiency, innovation, and sustainability
- Marketing partnerships with **retail chains and online marketplaces** to expand reach
- Sale agreements for tissue culture plantlets and horticultural produce
---
#### **5. Capacity Building & Education**
GVBL is committed to building a skilled workforce in agriculture and biotechnology.
- **GVBL Institute of High-Tech Agriculture & Biotechnology:**
- Established as an **Agricultural Training Centre** in collaboration with **Eden Horticulture Services, Karnal**
- Offers **paid training programs** for farmers and agri-entrepreneurs through the **Agri Skill Development Centre**
- **Centre of Excellence for Horticulture (Karnal, Haryana):**
- Equipped with poly houses, NFT/DFT systems, and a fully functional tissue culture lab
- Serves as a model for **technology-driven, profitable farming**
---
### **Strategic Initiatives (Dec 2024 Outlook)**
- **Dual Market Strategy:** Expand **B2B research collaborations** while strengthening **B2C personalized genetic and wellness services**
- **Wet-Lab Expansion:** Establish in-house NGS and Molecular Genetics lab to reduce dependency and enhance data velocity
- **FaaS (Farming as a Service):** Develop affordable, technology-driven farm management solutions for small and commercial farmers
- **Global RPO Leadership:** Scale Research Process Outsourcing to serve international genomics projects
- **Sustainability Integration:** Advance climate-resilient farming practices and reduce agricultural carbon footprint
---
### **Key Achievements (2020–2023)**
| Year | Milestones |
|------|-----------|
| **2020** | Formation of Farmers Producer Company (300 farmers), launch of Plant Tissue Culture Lab, entry into greenhouse cultivation |
| **2021** | Establishment of Centre of Excellence, launch of Farm 2 Doorstep, initiation of drone tech and Israeli pest control partnerships |
| **2023** | Expansion of FPC, secured retail & e-commerce distribution, signing of Israeli tech agreements, launch of Agri Skill Development Centre |